Titre : Érythrokératodermie variabilis

Érythrokératodermie variabilis : Questions médicales fréquentes

Termes MeSH sélectionnés :

Complement C5
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Érythrokératodermie variabilis : Questions médicales les plus fréquentes", "headline": "Érythrokératodermie variabilis : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Érythrokératodermie variabilis : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-24", "dateModified": "2025-03-21", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Érythrokératodermie variabilis" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Maladies génétiques de la peau", "url": "https://questionsmedicales.fr/mesh/D012873", "about": { "@type": "MedicalCondition", "name": "Maladies génétiques de la peau", "code": { "@type": "MedicalCode", "code": "D012873", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C17.800.827" } } }, "about": { "@type": "MedicalCondition", "name": "Érythrokératodermie variabilis", "alternateName": "Erythrokeratodermia Variabilis", "code": { "@type": "MedicalCode", "code": "D056266", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Yuuki Kodama", "url": "https://questionsmedicales.fr/author/Yuuki%20Kodama", "affiliation": { "@type": "Organization", "name": "Institute of Agricultural and Life Sciences, Academic Assembly, Shimane University, Matsue-shi, Japan. kodama@life.shimane-u.ac.jp." } }, { "@type": "Person", "name": "Matthew E M Yunik", "url": "https://questionsmedicales.fr/author/Matthew%20E%20M%20Yunik", "affiliation": { "@type": "Organization", "name": "Department of Biology, University of Saskatchewan, Saskatoon, SK, Canada." } }, { "@type": "Person", "name": "Neil B Chilton", "url": "https://questionsmedicales.fr/author/Neil%20B%20Chilton", "affiliation": { "@type": "Organization", "name": "Department of Biology, University of Saskatchewan, Saskatoon, SK, Canada." } }, { "@type": "Person", "name": "Chulantha P Diyes", "url": "https://questionsmedicales.fr/author/Chulantha%20P%20Diyes", "affiliation": { "@type": "Organization", "name": "Department of Biology, University of Saskatchewan, Saskatoon, SK, Canada." } }, { "@type": "Person", "name": "Mirye Park", "url": "https://questionsmedicales.fr/author/Mirye%20Park", "affiliation": { "@type": "Organization", "name": "Protist Research Team, Microbial Research Department, Nakdonggang National Institute of Biological Resources, Sangju, 37242, Republic of Korea." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Three-Dimensional (3D) deep learning model complements existing models for preoperative disease-free survival prediction (DFS) in localized clear cell renal cell carcinoma (ccRCC): A multicenter retrospective cohort study.", "datePublished": "2024-06-19", "url": "https://questionsmedicales.fr/article/38896853", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/JS9.0000000000001808" } }, { "@type": "ScholarlyArticle", "name": "Bullous pemphigoid induced by IgG targeting type XVII collagen non-NC16A/NC15A extracellular domains is driven by Fc gamma receptor- and complement-mediated effector mechanisms and is ameliorated by neonatal Fc receptor blockade.", "datePublished": "2023-11-06", "url": "https://questionsmedicales.fr/article/37929639", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/path.6220" } }, { "@type": "ScholarlyArticle", "name": "Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of T", "datePublished": "2023-05-07", "url": "https://questionsmedicales.fr/article/37150813", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/cup.14442" } }, { "@type": "ScholarlyArticle", "name": "A Greater Increase in Complement C5a Receptor 1 Level at Onset and a Smaller Decrease in Immunoglobulin G Level after Recovery in Severer Coronavirus Disease 2019 Patients: A New Analysis of Existing Data with a New Two-Tailed", "datePublished": "2023-08-28", "url": "https://questionsmedicales.fr/article/37759576", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/biology12091176" } }, { "@type": "ScholarlyArticle", "name": "Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.", "datePublished": "2022-07-19", "url": "https://questionsmedicales.fr/article/35868613", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.trim.2022.101672" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies de la peau et du tissu conjonctif", "item": "https://questionsmedicales.fr/mesh/D017437" }, { "@type": "ListItem", "position": 3, "name": "Maladies de la peau", "item": "https://questionsmedicales.fr/mesh/D012871" }, { "@type": "ListItem", "position": 4, "name": "Maladies génétiques de la peau", "item": "https://questionsmedicales.fr/mesh/D012873" }, { "@type": "ListItem", "position": 5, "name": "Érythrokératodermie variabilis", "item": "https://questionsmedicales.fr/mesh/D056266" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Érythrokératodermie variabilis - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Érythrokératodermie variabilis", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Érythrokératodermie variabilis", "description": "Comment diagnostiquer l'érythrokératodermie variabilis ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels signes cliniques indiquent cette maladie ?\nL'érythrokératodermie variabilis est-elle héréditaire ?\nPeut-on confondre cette maladie avec d'autres ?", "url": "https://questionsmedicales.fr/mesh/D056266?mesh_terms=Complement+C5&page=172#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Érythrokératodermie variabilis", "description": "Quels sont les principaux symptômes ?\nLes symptômes varient d'une personne à l'autre ?\nY a-t-il des symptômes associés ?\nLes symptômes s'aggravent-ils avec le temps ?\nLes symptômes peuvent-ils être déclenchés par des facteurs externes ?", "url": "https://questionsmedicales.fr/mesh/D056266?mesh_terms=Complement+C5&page=172#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Érythrokératodermie variabilis", "description": "Peut-on prévenir l'érythrokératodermie variabilis ?\nComment gérer les symptômes au quotidien ?\nY a-t-il des conseils pour la peau ?\nLes soins de la peau sont-ils importants ?\nLes patients doivent-ils éviter certains aliments ?", "url": "https://questionsmedicales.fr/mesh/D056266?mesh_terms=Complement+C5&page=172#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Érythrokératodermie variabilis", "description": "Quels traitements sont disponibles ?\nLes traitements sont-ils efficaces ?\nDes traitements alternatifs existent-ils ?\nLes traitements nécessitent-ils un suivi médical ?\nY a-t-il des effets secondaires aux traitements ?", "url": "https://questionsmedicales.fr/mesh/D056266?mesh_terms=Complement+C5&page=172#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Érythrokératodermie variabilis", "description": "Quelles complications peuvent survenir ?\nL'érythrokératodermie variabilis augmente-t-elle le risque de cancer ?\nLes complications affectent-elles la qualité de vie ?\nDes complications psychologiques peuvent-elles survenir ?\nLes complications nécessitent-elles une intervention médicale ?", "url": "https://questionsmedicales.fr/mesh/D056266?mesh_terms=Complement+C5&page=172#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Érythrokératodermie variabilis", "description": "Quels sont les facteurs de risque connus ?\nL'environnement joue-t-il un rôle ?\nLes infections peuvent-elles déclencher des symptômes ?\nLe stress influence-t-il la maladie ?\nY a-t-il des groupes à risque spécifique ?", "url": "https://questionsmedicales.fr/mesh/D056266?mesh_terms=Complement+C5&page=172#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer l'érythrokératodermie variabilis ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen clinique et l'historique familial, parfois confirmé par une biopsie cutanée." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques peuvent être effectués pour identifier des mutations spécifiques associées à la maladie." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent cette maladie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des plaques rouges et squameuses sur la peau, souvent avec des zones de kératose, sont typiques." } }, { "@type": "Question", "name": "L'érythrokératodermie variabilis est-elle héréditaire ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est généralement transmise de manière autosomique dominante dans les familles." } }, { "@type": "Question", "name": "Peut-on confondre cette maladie avec d'autres ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut être confondue avec d'autres dermatoses comme le psoriasis ou l'ichtyose." } }, { "@type": "Question", "name": "Quels sont les principaux symptômes ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des plaques rouges, des démangeaisons et une peau squameuse." } }, { "@type": "Question", "name": "Les symptômes varient d'une personne à l'autre ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'intensité et l'étendue des symptômes peuvent varier considérablement entre les individus." } }, { "@type": "Question", "name": "Y a-t-il des symptômes associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies des ongles et des cheveux peuvent également être observées chez certains patients." } }, { "@type": "Question", "name": "Les symptômes s'aggravent-ils avec le temps ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent fluctuer, mais ils ont tendance à persister tout au long de la vie." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils être déclenchés par des facteurs externes ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des facteurs comme le stress, les infections ou les irritants cutanés peuvent aggraver les symptômes." } }, { "@type": "Question", "name": "Peut-on prévenir l'érythrokératodermie variabilis ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Étant une maladie génétique, il n'existe pas de méthode de prévention connue." } }, { "@type": "Question", "name": "Comment gérer les symptômes au quotidien ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "L'utilisation régulière d'émollients et l'évitement des irritants cutanés peuvent aider." } }, { "@type": "Question", "name": "Y a-t-il des conseils pour la peau ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Il est conseillé de garder la peau hydratée et de protéger les zones affectées du soleil." } }, { "@type": "Question", "name": "Les soins de la peau sont-ils importants ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des soins appropriés peuvent réduire l'inconfort et améliorer l'apparence de la peau." } }, { "@type": "Question", "name": "Les patients doivent-ils éviter certains aliments ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Il n'y a pas de régime spécifique, mais une alimentation équilibrée peut soutenir la santé globale." } }, { "@type": "Question", "name": "Quels traitements sont disponibles ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des émollients, des corticostéroïdes topiques et des thérapies systémiques." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements peuvent aider à soulager les symptômes, mais il n'existe pas de cure définitive." } }, { "@type": "Question", "name": "Des traitements alternatifs existent-ils ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies comme la photothérapie peuvent être envisagées pour certains patients." } }, { "@type": "Question", "name": "Les traitements nécessitent-ils un suivi médical ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier est essentiel pour ajuster les traitements et surveiller les effets secondaires." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires aux traitements ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains traitements peuvent entraîner des effets secondaires comme l'amincissement de la peau." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des infections cutanées peuvent survenir en raison de la peau endommagée et des lésions." } }, { "@type": "Question", "name": "L'érythrokératodermie variabilis augmente-t-elle le risque de cancer ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Il n'y a pas de preuve claire que cette maladie augmente le risque de cancer de la peau." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes et les complications peuvent avoir un impact significatif sur la qualité de vie." } }, { "@type": "Question", "name": "Des complications psychologiques peuvent-elles survenir ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'impact esthétique et les démangeaisons peuvent entraîner des problèmes psychologiques." } }, { "@type": "Question", "name": "Les complications nécessitent-elles une intervention médicale ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines complications peuvent nécessiter des soins médicaux supplémentaires pour être gérées." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque connus ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux de la maladie sont le principal facteur de risque identifié." } }, { "@type": "Question", "name": "L'environnement joue-t-il un rôle ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Bien que l'environnement ne soit pas un facteur direct, des irritants peuvent aggraver les symptômes." } }, { "@type": "Question", "name": "Les infections peuvent-elles déclencher des symptômes ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines infections cutanées peuvent exacerber les symptômes de la maladie." } }, { "@type": "Question", "name": "Le stress influence-t-il la maladie ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut aggraver les symptômes et provoquer des poussées cutanées." } }, { "@type": "Question", "name": "Y a-t-il des groupes à risque spécifique ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes ayant des antécédents familiaux sont plus susceptibles de développer la maladie." } } ] } ] }

Sources (1719 au total)

Three-Dimensional (3D) deep learning model complements existing models for preoperative disease-free survival prediction (DFS) in localized clear cell renal cell carcinoma (ccRCC): A multicenter retrospective cohort study.

Current prognostic models have limited predictive abilities for the growing number of localized (stage I-III) ccRCCs. It is therefore crucial to explore novel preoperative recurrence prediction models... Patients with localized ccRCC were retrospectively enrolled from six independent medical centers. Three-dimensional (3D) tumor regions from CT images were utilized as input to architect a ResNet 50 mo... 707 patients with localized ccRCC were finally enrolled for models' training and validating. The DLCR we established can perfectly stratify patients into low-, intermediate- and high-risks, and outper... Our deep learning model, derived from preoperative CT, is superior to radiomics and current models in precisely DFS predicting of localized ccRCC, and can provide complementary values to them, which m...

Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of T

Immune checkpoint inhibitor (ICI)-based cancer therapies cause a variety of cutaneous immune-related adverse events (irAEs) including immunobullous skin eruptions like bullous pemphigoid (BP). However... BP-irAE (n = 8) and de novo BP control (n = 8) biopsy samples were subjected to gene expression profiling using the NanoString® Technologies nCounter PanCancer Immune Profiling Panel. Multiplex immuno... Compared with de novo BP controls, BP-irAE samples exhibited upregulation of 30 mRNA transcripts (p < 0.025), including toll-like receptor 4 (TLR4) and genes associated with complement activation, and... BP-irAE exhibited activation of the TLR4/complement-driven classical innate immune response pathway, with dermal T...

Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.

It is controversial whether all donor-specific antibodies (DSA) detected by the solid-phase single antigen bead (SAB) assay negatively affect kidney transplantation outcomes. The study aimed to evalua... From the historical cohort of living donor recipients transplanted between 2014 and 2018 at our center (n = 82), 55 patients met the inclusion criteria, namely: these patients were > 18 years old with... In the studied cohort, DSA-positive, NDSA reactive, and anti-HLA negative recipients constituted 33%, 36%, and 31% of 55 patients, respectively. Non-routinely considered pre-transplant HLA-DQ, -DP, an... Our 3-year follow-up of patients with low pre-transplant DSA found no association with a deterioration in graft function and worse graft survival. Furthermore, we did not observe an increase in AMR in...

Adjuvant Wilms' tumour 1-specific dendritic cell immunotherapy complementing conventional therapy for paediatric patients with high-grade glioma and diffuse intrinsic pontine glioma: protocol of a monocentric phase I/II clinical trial in Belgium.

Diffuse intrinsic pontine glioma (DIPG) and paediatric high-grade glioma (pHGG) are aggressive glial tumours, for which conventional treatment modalities fall short. Dendritic cell (DC)-based immunoth... 10 paediatric patients with newly diagnosed or pretreated HGG or DIPG were treated according to the trial protocol. The trial protocol consists of leukapheresis of mononuclear cells, the manufacturing... The ethics committee of the Antwerp University Hospital and the University of Antwerp granted ethics approval. Results of the clinical trial will be shared through publication in a peer-reviewed journ... NCT04911621....

Complement component 5a receptor 1 and leukotriene B4 receptor 1 regulate neutrophil extracellular trap (NET) formation through Rap1a/B-Raf/ERK signaling pathway and their deficiency in term low birth weight newborns leads to deficient NETosis.

Neutrophil extracellular traps (NETs) being one of the predominant activities of neutrophils has become its key defense mechanism owing to its extensive role in inflammation and infection. However, th... The validation of the transcriptomic data for C5aR1 and LTB4R1 was done using quantitative real time PCR. Pharmacological inhibition of C5aR1 and LTB4R1 using W-54011 and LY223982 on neutrophils of ad... The expression of C5aR1 and LTB4R1, extracellular DNA, ROS and NET associated proteins (NE, CitH3, PAD4 and MPO) was notably increased upon NET induction in healthy adults and normal birth weight (NBW... The C5aR1 and LTB4R1 signaling via Rap1a/B-Raf/ERK axis acts as a signal-relay mechanism to regulate NET formation in neutrophils. Further, C5aR1 and LTB4R1 signaling cascade along with NET-associated...

The Use of Fissios App© as a Complement to a Face-to-Face Respiratory Physiotherapy Program versus an Attendance-Only Face-to-Face Physiotherapy Program in Patients Scheduled for Thoracic Surgical Procedures Reduces the Risk of Developing Postoperative Pulmonary Complications-A Quasi-Experimental Study.

Postoperative pulmonary complications (PPCs) increase the hospital length of stay (LOS) and the cost of healthcare associated with surgical procedures. Strategies to reduce PPCs begin before surgery a...